Introduction
Convulsive status epilepticus (CSE) is the most common emergency in paediatric neurological practice [1] . Epidemiological studies suggest that there are approximately 20 episodes of CSE per 100,000 children per year [2] and that approximately one in eight (12%) of all first seizures present as CSE [3] . Previously, CSE was defined as a seizure lasting longer than 30 min or two or more seizures within 30 min without a return to the individual's baseline level of consciousness between seizures (Appendix A). The definition has evolved to be a seizure-duration of longer than 5 min or two or more seizures without a return of consciousness between seizures. Serial seizures are defined as three or more tonic-clonic seizures in Aims: To obtain national epidemiological data on the aetiology, management and outcome of refractory convulsive status epilepticus (RCSE) in children. Methods: Data on children admitted with RCSE between 01.01. 2008 and 31.12.2009 , to eight paediatric intensive care units (PICUs) were retrospectively collected using a standard proforma designed with and co-ordinated by PICANet. Results: Data were collected on 245 (male, 179) patients aged between <1 month and 16.5 years (median 2.8 years, IQR 1-7.43 years), of which:
One hundred and fifty-one patients (male, 89) aged between <1 month and 16.5 years (median 2.3 years, IQR 1-7.17 years) met the study criteria for a diagnosis of RCSE. Causes included acute symptomatic (15.2%), remote symptomatic (29.0%), epilepsy-related (10.6%), progressive encephalopathy (10.6%) febrile seizures (18.2%); no cause was identified in 16.4%.
First line treatments included lorazepam (118 patients, 78.1%), diazepam (72, 47 .7%) and midazolam (37, 24 .5%).
Second-line treatments included phenytoin (125 patients, 82.8%) and phenobarbital (seven patients, 4.6%).
Third-line treatments included a thiopentone bolus (99 patients, 65.6%), thiopentone infusion (20, 13.2%) midazolam infusion (56, 37 .1%) phenobarbital (18, 11 .9%), propofol (6, 4 .0%) and clonazepam (2, 1.3%). Deviation from the national advanced paediatric life support (APLS) protocol was noted in approximately one quarter of all patients.
Six patients died (4.0%). Seventeen patients (11.3%) developed a new neurological deficit on discharge from PICU, of which eight (5.3%) continued to show this deficit at a 30-day follow-up and 12 patients (7.9%) developed de novo epilepsy. Conclusions: Thiopentone was the most commonly used anticonvulsant to treat RCSE on admission to PICU. Mortality was low and approximately 1 in 25 showed a new neurological deficit at the 30-day follow-up.
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1 h [4] . Current treatment protocols reflect the urgency of CSE and recommend that treatment should be given if a tonic-clonic seizure has lasted for 5 min [5, 6] . There is evidence that seizures lasting longer than 30 min are unlikely to stop without intervention [7] [8] [9] , and that prolonged ictal activity, whether or not it is associated with continued clinical (and specifically motor) seizures, causes excitatory amino-acid neurotoxicity-mediated death [10, 11] Refractory convulsive status epilepticus (RCSE) may be associated with significant mortality and morbidity [10] . It is less common than CSE and is relatively poorly understood. This is reflected in the continuing debate over its definition with investigators focusing on the duration of the initial tonic-clonic seizure or the number of anticonvulsants that have failed to terminate the seizure, or a combination of both [12, 13] . Previously used criteria included 30 [14] or 60 min [15, 16] and failure to respond to either two [14, 17] , or three drugs [18, 19] . At least one definition suggested that ''electrographic seizures'' would be as acceptable as clinical seizures [20] .
The incidence of RCSE is unknown. Adult data suggest that 31-38% [19] patients in CSE will subsequently progress to RCSE. Thirty six per cent of patients have an established diagnosis of epilepsy [21] . RCSE accounted for 4% of admissions to a UK tertiary PICU over a 10-year period [22] .
Within the past few years, the Advanced Paediatric Life Support (APLS) Group [23] and the UK National Institute for Health and Clinical Excellence (NICE) [24] have established evidence-based protocols and guidelines for the management of tonic-clonic seizures that have not stopped spontaneously after 5 min [23, 24] . These protocols now include out of hospital-administered benzodiazepines within the total number of benzodiazepine doses that can be given; the omission of rectal paraldehyde (because of concern that excessive benzodiazepine use or the use of rectal paraldehyde, or both, may cause respiratory depression) [25] and an increase in the initial loading dose of intravenous phenytoin from 18 to 20 mg/kg. In contrast to CSE, there is no clear international guidance on the management of RCSE [13] .
This multicenter study from the UK was conceived to obtain national data on the demographics, aetiology, management and outcome of RCSE in children presenting to paediatric intensive care units (PICUs) in England and Scotland over a two-year period. The primary aim was to describe current practice in drug treatment of RCSE, with particular focus on the third-line treatments and to identify areas for future research.
As a secondary aim, the study also assessed adherence to the national APLS CSE algorithm, as it was considered that management of CSE may influence both the incidence and outcome of RCSE [24] .
Methodology

Definitions (Appendix B)
The definition of RCSE used in the study is based on the failure to respond to anticonvulsants rather than seizure duration. It was defined as the failure of the presenting episode of CSE to terminate with a first-line anticonvulsant, a benzodiazepine (buccal or intravenous or both) and a second-line anticonvulsant (phenytoin or phenobarbital or sodium valproate). This is similar to other previous [16, 17] , and more recently-used definitions of RCSE [13] . The duration of the CSE was not a defining criterion in the current study.
Inclusion criteria
All patients aged <16 years that presented to PICU with RCSE (as defined above). . Data included patients admitted directly to the hospital in which the PICU was situated and patients transferred in from district general hospital (DGH) satellite Accident and Emergency (A + E) departments. The study was conducted over two years because it was considered that one year's data would be limited due to the rarity of RCSE.
Data collection
Initial data on the diagnosis, demographics and course during PICU admission were collected on all PICU admissions in the participating centres by the PICANet team in Leicester. All patients who fulfilled the criteria for RCSE subsequently had data retrospectively collected from the case notes and entered on a proforma used in all participating centres. Data were downloaded for analysis on 1.8.2012.
Data analysis
Data analysis were undertaken with Microsoft Excel and included demographics, aetiology, previous diagnosis of epilepsy, length and treatment of the presenting tonic-clonic seizure (episode of CSE), treatment, efficacy of third-line anticonvulsants and short-term outcomes.
The aetiology of RCSE was classified into five categories using an established classification (Appendix B): prolonged febrile convulsion (PFC), acute symptomatic (AS), remote symptomatic (RS), idiopathic epilepsy-related (IER), progressive encephalopathy (PE) and unclassified (U); the latter included patients with insufficient information to identify a cause [1] .
The efficacy (success) of third-line anticonvulsant drugs was considered based on the following criteria: a medication was judged to have been successful if the RCSE was terminated with resolution of seizures for a minimum of 30 min, in accordance with the widely accepted definition of CSE (Appendix A). If a patient had a subsequent seizure after a 30-min seizure free period, this was defined as a separate episode of CSE; these patients were not included in the analysis. A medication was judged to have failed if another third-line medication was required to terminate the presenting seizure.
Clinical outcomes assessed included death, the development of any new neurological deficit or of de novo epilepsy at the time of discharge from PICU and at 30-day follow-up. A neurological deficit was defined as any abnormality including tetraparesis, hemiparesis, ataxia or reported visual, auditory, cognitive or behavioural impairment. Epilepsy was not further classified into focal or generalized. All follow-up data were based on the patient's discharge or outpatient letters. No attempt was made to undertake any formal cognitive, behavioural or electroencephalographic (EEG) assessments at the 30-day follow-up as this was not within the remit of this audit.
The anticonvulsant management of RCSE was compared with the current APLS guideline. This guideline indicates that patients should receive two doses of benzodiazepine as first-line management of a seizure lasting more than 5 min. If the seizure persists after 10 min, phenytoin or phenobarbital are recommended as second-line agents and should be administered before the use of rapid sequence induction (RSI) or a continuous intravenous infusion of an anaesthetic agent (Fig. 4) . Fosphenytoin is not routinely available in the UK.
Results
Two hundred and forty-five patients were identified with possible RCSE from the PICANet database; 151 subsequently met the study criteria for definite RCSE. The median age of the population was 2.3 years (interquartile range, 1-7.17). Eighty-nine (58.9%) were males. Sixty-seven patients (44.4%) had an established diagnosis of epilepsy and were receiving at least one antiepileptic drug (AED) prior to presentation. Fifty-one males and 30 females had a history of at least two previous generalized tonicclonic seizures. There was no statistically significant difference between: the ages of the patients of each sex (p = 0.67), the number of patients of each sex with a previous diagnosis of epilepsy (p = 0.62) or the number of patients of each sex with previous generalized tonic-clonic seizures (p = 0.22) ( Table 1 ). All other results are given in descriptive format.
Aetiology of RCSE (Figs. 1-3)
This varied within age groups. Under one year of age, acute symptomatic (AS) causes were the most common (28.5%); between one and five years of age, prolonged febrile convulsions (PFC) were the most common (33.8%); in both the over five years of age and 10-16 year-old groups, remote symptomatic seizures (RS) were the most common (40% and 36.8% respectively).
Overall, the most frequent aetiologies of RCSE were RS (29% of all patients), PFC (18.2%), AS (15.2%) and PE and IE (both 10.6%). (Table 2) Intravenous lorazepam was the most commonly used first-line anticonvulsant, with 118 patients receiving 182 doses. Seventytwo patients received 94 doses of diazepam (rectally or intravenously) and 37 patients received 67 doses of buccal midazolam.
Intravenous phenytoin was the most commonly used secondline anticonvulsant (125 patients, 82.8%). The remaining patients received intravenous phenobarbital (seven, 4.6%) multiple intravenous doses of a benzodiazepine (eight, 5.3%) or an alternative second-line drug (11, 7.3%). Second-line drugs included sodium valproate (five), clonazepam (two), pyridoxine (two), vigabatrin (two), biotin (one), folinic acid (one), and carbamazepine (one); some patients received more than one second-line drug.
Third-line anticonvulsants and efficacy (Table 2)
Ninety-nine patients received a thiopentone bolus, with termination of the seizure (episode of RCSE) in 46 (46.5%).
Twenty patients were commenced on a thiopentone infusion with termination of the seizure in eight (40%).
Fifty-six patients were commenced on a continuous intravenous (cIV) midazolam infusion, with termination of the seizure in 25 (44.6%).
If phenobarbital was administered following the failure of a first and second-line drug, it was defined as a third-line agent. Eighteen patients received phenobarbital and this terminated the seizure in four (22.2%).
Six patients received propofol, with seizure-termination in two (33.3%).
Two patients were commenced on a clonazepam infusion, with seizure-termination in both cases (100%).
It was not possible to identify which third-line anticonvulsant was efficacious in terminating RCSE in 64 patients (42.4%) because they received more than one treatment and the responses to each drug were not recorded. (Table 3) All patients had a recorded outcome at their discharge from PICU; only 59 (39.1%) had a recorded outcome for their 30-day follow up.
Six patients (4%) died during the PICU admission. Seventeen (11.3%) manifest a new neurological deficit noted on discharge from PICU and this deficit had persisted at the 30-day follow-up in eight (47%) of these patients. Eight of these patients (47%) were part of the group in which no 30-day follow-up was recorded and consequently the neurological deficit at the 30-day follow-up was classified as 'unknown'.
Twelve of the 59 patients (20.3% or 7.9% of all 151 patients) were diagnosed with de novo epilepsy at the 30-day follow-up.
Mortality and all morbidities were more frequently observed in patients with an acute symptomatic (AS) aetiology and in those patients aged less than one year of age at presentation. It was not clear from the data collected whether the seizures were judged to have terminated using EEG, CFM or clinical assessment. (Fig. 4) Deviations from the APLS protocol were recorded in 36 patients (23.8%) and were categorized as: excessive numbers of doses of benzodiazepines (eight patients, 5.3%), use of an alternative second-line drug (eight patients, 5.3%), excessive numbers of doses of a second-line drug prior to the initiation of third line treatment (nine patients, 6%) and rapid sequence induction with thiopentone prior to the administration of a second-line anticonvulsant (11 patients, 7.3%). There was no documentation to explain or justify these deviations. Outcomes in these patients were no different from those treated according to the protocol.
Deviations from APLS
Discussion
Demographics and aetiology
As far as we are aware this is the largest published study that reports unique data on a large number of children with RCSE. Fifty nine percent of the patients were male and 58% were aged five years or under, similar to previous findings [5, 21, 26, 27] . Patients with a remote symptomatic (RS) cause were the most common group (45 of 151, 29.8%), in contrast to previous studies which demonstrated prolonged febrile convulsions (PFC) to be the most common cause of convulsive status epilepticus (CSE). However, it must be emphasized that our study focused on refractory CSE (RSCE), and not CSE. 
Outcome
Mortality
Previous studies of all-age RCSE have reported mortality rates of 16-32% [5, 14, 21, [27] [28] [29] [30] . Several larger studies of non-refractory CSE, but which included a small cohort with RCSE, including a cohort of 22 children aged 4.5 months to 18 years [28] reported a mortality of 0-22% [5, 21, 31] . Our figure of 4.0% is at the lower end of these data.
Morbidity
Limited data have reported a wide range of outcomes in paediatric RCSE; two small studies described 45-100% of survivors experiencing long-term neurological deficits [28, 29] . In studies which examined both refractory and non-refractory CSE, the reported prevalence of de novo epilepsy varied from 5.1% [21] to 30% [6, 28, 32, 33] and new neurological sequelae from 2.2% to 29.8% [5, [32] [33] [34] [35] .
Although the 30-day follow is likely to be too brief a period to identify all diagnoses of de novo epilepsy, this was recorded in 12 patients (7.9% of the all 151 patients). Just over five per cent (5.3%) demonstrated a new neurological deficit on discharge from hospital and which had persisted at the 30-day follow up. Both of these figures are within the ranges reported in the earlier studies described above.
Clearly, the short-term outcome morbidity (new neurological deficit and de novo epilepsy) data from the current study are very limited and it would be important to repeat this audit with more detailed and formal, including developmental/cognitive and psychological long-term outcome data.
Aetiology and risk factors
Most adverse outcomes occur in patients with an acute symptomatic (AS) aetiology or an underlying progressive encephalopathy (PE). These findings have been reproduced in studies that have specifically assessed refractory seizures [14, 28, 29] and in studies where prolonged seizures or PICU admission were the only inclusion criteria [15, 27, 32, 34, 35] . Although improved outcomes have been associated with febrile CSE [35] , developmental deficits are still demonstrable on follow up compared to controls. Our data support these observations; patients with acute symptomatic seizures accounted for 55.5% (five of nine patients) with a new neurological morbidity at the 30-day follow-up and 50% (three of six) deaths. There is some evidence that aetiology is a risk factor independent of seizure duration [34] . Where aetiology was not controlled for, duration of seizure has been suggested as an independent factor [32] .
New neurological sequelae more commonly occur in children under one year of age. This may be explained by the relatively higher incidence of an acute symptomatic (AS) cause of CSE (29% of children <one year of age will develop a new neurological deficit following CSE vs 6% in children aged >three years [15] ). However, improvement is also more commonly seen in younger children; in one study of non-refractory CSE, 28% of <3 year-olds improved and 20% became neurologically normal in contrast to 5% and 0% of >5 year-olds respectively [22] .
Treatment
First-line agents
Benzodiazepines are the universal first-line anticonvulsant used to terminate a tonic-clonic seizure that has lasted for more than 5 min. Non-intravenous midazolam controls CSE in 48-56% [26, 36] of patients. Response rates with diazepam are similar (23-56%) [37] [38] [39] and there is no difference in the rates of respiratory depression between the two drugs [36] . Buccal midazolam is the preferred choice for parents, carers and school nurses for prolonged seizures because of its easier and more acceptable route of administration.
In our data, intravenous lorazepam was the most frequently administered first-line intravenous medication (78.1%). It is considered to be the most effective first-line intravenous therapy (59-65% response in adults [37, 38] and 73-76% in children [39, 40] ). In the UK, it is the first-choice treatment in all patients with established intravenous access [23, 24, 41] .
Eight patients (5.3%) received a higher total dose of benzodiazepine over the course of their management than that recommended by the current APLS guidelines (Fig. 4) or the British National Formulary for Children (BNFc). An epidemiological study reported a possible correlation between the number (and doses) of pre-hospital benzodiazepines and respiratory depression and the requirement for PICU admission [25] . Phenobarbital was shown to be more effective than a combination of diazepam and phenytoin and with a similar incidence of adverse side-effects when used in a randomized, nonblinded clinical trial of 36 consecutive patients with generalized convulsive status epilepticus [42] .
Second-line agents
Phenytoin was the most commonly used second-line drug (80% of patients), which reflects its position in the APLS guideline. Its reported efficacy is 15% [8, 26] -55.8% [43] , the latter when administered with a benzodiazepine. Phenobarbital is also an effective second-line agent [43] [44] [45] and might be of additional benefit if cerebral oedema is a contributing factor [44] .
Levetiracetam may replace phenytoin as the standard secondline treatment [46] because of its linear pharmacokinetics, low cardiovascular toxicity, absence of any tissue extravasation-injury and very few drug interactions [12] . Adult data have shown a response rate of 22-88%; there are minimal paediatric randomized controlled trial data [45, 47] .
The potential role of other second-line agents has not been extensively studied in children [44] . Adult data suggest that sodium valproate may be more effective than phenytoin with a reported efficacy of 45-92.5% [48] [49] [50] .
Six per cent of our patients received more than one dose of second-line anticonvulsant prior to anaesthesia. One explanation for this deviation from the APLS guideline is that specific patients may have a personalized care plan [24] , based upon their specific epilepsy syndrome, previous admissions and response(s) to emergency (rescue) anticonvulsants and the desire to avoid ventilating seriously neurologically disabled children. It was not possible to confirm or refute this hypothesis as these data were not collected.
Reduced efficacy of repeated doses of second-line treatments have been demonstrated in adults; 56% responded to first-line treatment, 7% to second line and 2.3% to a third-line, nonanaesthetic drug [41] . Phenobarbital was effective in only 2.1% of cases following failure of benzodiazepines and phenytoin. [51] In our patients, 22.2% showed a response to phenobarbital when administered as a third-line agent, as compared to 46.5% following a thiopentone bolus, 40% following a thiopentone infusion and 44.6% following a continuous midazolam infusion.
Third-line agents
The majority of our patients received midazolam or thiopentone, similar to previous data [21] . A single thiopentone bolus was given to 99 patients, terminating RCSE in 46.5%. For those patients that required a continuous intravenous infusion to terminate the seizure (rather than to maintain anaesthesia), midazolam was the most frequently used medication, followed by thiopentone. The rate of efficacy for both drugs was similar (midazolam, 44.6% and thiopentone, 40%). Propofol was used very infrequently and no patient was treated with a cIV of diazepam.
The efficacy of midazolam has been previously demonstrated. In one series, midazolam infusion controlled status in 26 of 27 children in whom status had already lasted for 60 min and had been refractory status to diazepam, phenytoin and phenobarbital. [52] Another series randomized 40 children (aged 2-14 years) with RCSE following a diazepam bolus and phenytoin infusion to a No data 64 PICU = paediatric intensive care unit, RCSE = refractory convulsive status epilepticus. Infusions were administered via continuous intravenous drip and varied in concentrations and rate of administration between patients. It was not clear which drug was efficacious in terminating seizures in 64 patients. a Further benzodiazepines = further doses of a benzodiazepine were administered after the patient had received the recommended maximum of two doses. b Sodium valproate (five patients); clonazepam (two patients); pyridoxine (two patients); vigabatrin (two patients); biotin (one patient); folinic acid (one patient) and carbamazepine (one patient); some patients received more than one secondline drug. cIV of diazepam or midazolam. Control of status was achieved in 89% of diazepam and 86% of midazolam-treated patients but seizure-recurrence was more common in the midazolam group (57% vs 16%) [53] . In general, cIV therapy to treat RCSE is associated with an increased risk of hypotension and respiratory depression, regardless of drug [43, [54] [55] [56] [57] . This risk may be lower with diazepam or midazolam than with thiopentone [14, 30, [58] [59] [60] . In addition, thiopentone may impair myocardial function and may also be immunosuppressive at high doses [58, 59] . One meta-analysis of paediatric RCSE concluded that treatment with thiopentone had a significantly higher mortality rate than midazolam (31% vs 0%) and recommended midazolam should be first choice for cIV treatment [14] . However, a systematic review of 19 studies of adult RCSE suggested that treatment failure was less common with thiopentone than with midazolam (3% vs 21% respectively) [56] . Unfortunately, there were significant discrepancies in the studies' designs and their outcomes with some using clinical, and others EEG control. Ninety eight percent of the thiopentone group had burstsuppression on EEG as an outcome measure compared with none in the midazolam group [56] . Concerns have been expressed over the use of burst-suppression as an endpoint because of potentially fatal multi-organ failure [56] [57] [58] [59] and doubts over its use as an endpoint for treatment [61] .
Opinion remains divided on the use of continuous infusions of propofol in paediatric RCSE, which reflects concern over the higher incidence of the propofol infusion syndrome in children than adults [21, 45] . The syndrome comprises of severe lactic acidosis, rhabdomyolysis, cardiovascular collapse and multi-organ failure and a high risk of death. However, a recent study demonstrated that an episode of RCSE was controlled in 14 of 22 propofol, and 11 of 20 thiopental-treated patients and thiopental was associated with more severe adverse side-effects [62] .
Sodium valproate [63] [64] [65] , may be as effective as cIV diazepam (80% vs 85% respectively) and is associated with less ventilatory or inotropic support or ICU admission [63] . This supports previous data which showed 78% efficacy in paediatric RCSE with no recorded adverse effects [64] .
Finally, reports have shown efficacy of ketamine [66] [67] [68] , topiramate [69] [70] [71] , and lacosamide [72] [73] [74] in adult RCSE and the ketogenic diet in children with severe RCSE secondary to a febrile encephalopathy (fever-induced refractory epileptic encephalopathy in school age children [FIRES]) [75] .
Deviation from the APLS protocol
Thirty-six patients were noted to have received treatment other than that recommended by the APLS guidelines (Fig. 4) . Given the extremely heterogeneous nature of these patients, and the relatively small numbers identified in each group it is not possible to assess whether any of these deviations had any impact on outcome.
Study limitations
This study clearly has a number of limitations, primarily the small number of participating centres.
Data that related to epidemiology and aetiology were collected prospectively on admission to PICU via the PICANet database and are robust and largely complete. Data that related to treatments given, response and follow-up were collated retrospectively from case notes and consequently are less complete. In particular, information about length of seizure and timing of cessation were incomplete and consequently, efficacy was based on whether or not there was seizure-termination per se, rather than the length of time until seizure-cessation. These factors are clearly important when determining the comparative efficacy of different infusions.
There were limited follow-up outcome data; 59 patients had their 30-day follow up recorded, including only nine of the 17 patients who had a new neurological deficit recorded at discharge from PICU. Based on these data, we have no knowledge of the outcomes for the remainder, the majority, of our patients. The long-term outcome (up to at least six months) of RCSE is important and should be included in any future, prospective audit and we would concur with the wide-ranging recommendations of the pSERG [13] .
Finally, the lack of randomization and control, as well as the high number of potentially confounding independent variables clearly precludes formal statistical analysis of the study population.
Despite these limitations the current study provides new and additional information including in demonstrating a low mortality and relatively low morbidity when compared with previous and much smaller study populations.
Conclusions
The current guidelines on management of CSE, and particularly RCSE are primarily based on best-perceived clinical practice [44] , with subsequent revisions made as and when evidence becomes available. Predictably, given the rarity of RCSE compared to CSE, there is a very limited evidence-base for its management, including the wide variation in the choice of the third-line anticonvulsant.
Our study has demonstrated a high rate of deviation from the national APLS guideline in the management of CSE which is the forerunner to RCSE. It was not possible to draw any definitive conclusions as to whether these deviations were associated with a poorer outcome in terms of mortality and morbidity because of the size of the population and insensitivity of the collected data. This would be important to evaluate in any further audit.
Continuous infusions of intravenous midazolam and thiopentone seemed to demonstrate similar efficacy. In view of the relatively poor safety profile of thiopentone, our data could support the use of midazolam as the preferred third-line treatment of RCSE; however, as stated earlier, there are significant limitations to this study and rigorously-conducted randomized controlled trials are required to confirm or refute this recommendation. This would allow for adequate control of the many potentially confounding variables and for detailed assessment of the patient's neurological status before and after each episode. Such an assessment should use a robust and validated disease severity scoring tool to provide objective evidence for the most effective and safest treatment.
The paediatric status epilepticus research group (pSERG) has recently published a comprehensive review of the current gaps in understanding and research opportunities in RCSE. The group emphasize the need for description of current practice and design of adequate trials to investigate all aspects of pharmacological management with which we would concur [13] . The current study represents the largest collection of such data and is an important step towards an evidence-based management of RCSE.
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